Switching to aripiprazole from other second-generation antipsychotics.

Phase 4

Recruiting

• Conditions: Schizophrenic and schizoaffective disorder; Mental Health - Schizophrenia

• Registration Number: ACTRN12605000516684
• Lead Sponsor: Bristol Meyers Squibb Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Schizophrenic and schizoaffective patients, who for clinical reasons are being switched from another SGA to aripiprazole, will be eligible for the study.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified